Evolocumab efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Evolocumab Efficacy in Lowering LDL Cholesterol and Cardiovascular Risk
Evolocumab, a PCSK9 inhibitor, has consistently shown strong efficacy in lowering low-density lipoprotein cholesterol (LDL-C) across diverse patient populations. In large clinical trials, evolocumab reduced LDL-C by 56–61% over periods ranging from 1 to 5 years when added to standard therapy, with reductions maintained throughout long-term follow-up Sabatine2015Koren2019Koren2014. In a 12-week study among Chinese patients, LDL-C reductions reached nearly 70% compared to placebo . Similar results were observed in Japanese patients, with LDL-C reductions of 65–69% over one year . In patients with type 2 diabetes, evolocumab lowered LDL-C by 54–65% and also improved other lipid parameters . For those with familial hypercholesterolemia, evolocumab and other PCSK9 inhibitors reduced LDL-C by about 50% .
Beyond lipid lowering, evolocumab has demonstrated a reduction in cardiovascular events. In a pooled analysis, the rate of cardiovascular events at one year was reduced by more than half compared to standard therapy alone . Meta-analyses confirm that evolocumab lowers the risk of myocardial infarction, stroke, and coronary revascularization, though effects on all-cause and cardiovascular death were not statistically significant .
Evolocumab Safety Profile and Adverse Events
Evolocumab is generally well tolerated, with most adverse events occurring at similar rates to standard therapy or placebo Sabatine2015Koren2019Tan2023+5 MORE. Serious adverse event rates during long-term use (up to 5 years) were comparable to standard care, and discontinuation due to adverse events was low (about 5.7%) . The incidence of neurocognitive events, liver enzyme elevations, and muscle-related side effects was not increased with evolocumab compared to controls Sabatine2015Guedeney2019Ghasempour2023. No neutralizing anti-drug antibodies were detected in long-term studies .
Evolocumab in Patients With and Without Diabetes
Evolocumab’s efficacy in lowering LDL-C and reducing cardiovascular risk is consistent in patients with and without diabetes Alraddadi2025Rosenson2019Sabatine2017. In the FOURIER trial, evolocumab did not increase the risk of new-onset diabetes or worsen glycemic control, even in those with prediabetes . However, a real-world study found a potential for worsened glycemic control in some patients, particularly those with diabetes, suggesting the need for further investigation . Overall, the majority of studies report no significant impact on glucose metabolism or diabetes risk Rosenson2019Sabatine2017.
Efficacy and Safety in Special Populations
Evolocumab is effective and safe in various populations, including those with familial hypercholesterolemia, type 2 diabetes, and different ethnic backgrounds (Chinese, Japanese, Middle Eastern) Alraddadi2025Tan2023Rosenson2019+3 MORE. The magnitude of LDL-C reduction and safety profile are consistent across these groups, though real-world studies may show slightly lower LDL-C reductions and target achievement rates compared to clinical trials .
Conclusion
Evolocumab provides robust and sustained LDL-C lowering and reduces the risk of major cardiovascular events in a wide range of patients, including those with diabetes and familial hypercholesterolemia. Its safety profile is favorable, with adverse events similar to standard therapy and no significant increase in neurocognitive, hepatic, or diabetes-related risks. While real-world data suggest possible effects on glycemic control in some patients, the overall evidence supports evolocumab as an effective and safe option for lipid management and cardiovascular risk reduction.
Sources and full results
Most relevant research papers on this topic
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Evolocumab plus standard therapy significantly reduced LDL cholesterol levels and the incidence of cardiovascular events over a 1-year period.
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
Evolocumab effectively lowers LDL-C levels in patients with hypercholesterolemia for up to 5 years, with no neutralizing antibodies detected in the longest-duration study of a PCSK9 inhibitor.
Evolocumab safety and efficacy in hypercholesterolemia patients with or without diabetes: a retrospective real-world analysis
Evolocumab effectively reduces LDL cholesterol in hypercholesterolemia patients, but may negatively impact glycemic control and may not achieve recommended LDL-C targets.
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
Alirocumab and evolocumab are associated with lower risk of myocardial infarction, stroke, and coronary revascularization, with a favorable safety profile.
One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies.
Evolocumab combined with standard of care is well-tolerated and effectively reduces LDL-C levels in Japanese patients with high cardiovascular risk.
Try another search
satellite distribution in low earth orbit
tumor imaging techniques
What are the best strategies for boosting sales through livestream commerce?
What is the relationship between perceived organizational support and employee engagement in remote work environments?
volume of matter
Large Hadron Collider construction and operating costs